![](https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/06/Simcere-shutterstock_2306228027.jpg)
China NMPA approves Simcere Zaiming’s Enlituo for mCRC treatment
The China National Medical Products Administration (NMPA) has granted marketing approval for Simcere Zaiming’s Enlituo for the treatment of metastatic colorectal cancer (mCRC). An anti-epidermal growth factor receptor antibody drug, Enlituo is developed by …